Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Kura Oncology Inc

Start price
Target price
Perf. (%)
€17.70
25.01.24
€16.00
31.08.25
9.60%
02.02.24

Could be very worthwhile Investment >20% year
buy
H&R GmbH & Co. KGaA

Start price
Target price
Perf. (%)
€4.80
23.01.24
€6.00
23.01.25
4.58%
03.02.24

Good culture
Revenue growth >5% per year expected
Capable Management
Little innovation
buy
Wasgau Produktions & Handels AG

Start price
Target price
Perf. (%)
€10.90
23.01.24
-
23.01.25
-6.42%
03.02.24

Top 10 in its market
Future proof or reliable business model
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
buy
Coherus Bioscien.

Start price
Target price
Perf. (%)
€2.21
23.01.24
-
23.01.25
-15.48%
03.02.24

Probably not worthwhile Investment
buy
G1 Therapeutics

Start price
Target price
Perf. (%)
€3.38
22.01.24
-
22.01.25
14.50%
03.02.24

Could be very worthwhile Investment >20% year
buy
Coherus Bioscien.

Start price
Target price
Perf. (%)
€2.92
22.01.24
-
22.01.25
-36.03%
03.02.24

Probably not worthwhile Investment
buy
Actinium Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€4.54
21.01.24
-
21.01.25
6.61%
03.02.24

Could be worthwhile Investment >10% per year
buy
ProQR Therapeutics N.V.

Start price
Target price
Perf. (%)
€1.67
21.01.24
-
21.01.25
18.80%
03.02.24

Could be worthwhile Investment >10% per year
buy
Mersana Therapeutics

Start price
Target price
Perf. (%)
€2.44
21.01.24
-
21.01.25
23.55%
03.02.24

Could be worthwhile Investment >10% per year
buy
TG Therapeutics Inc.

Start price
Target price
Perf. (%)
€13.91
21.01.24
-
21.01.25
7.87%
03.02.24

Could be very worthwhile Investment >20% year
buy
Cytokinetics Inc.

Start price
Target price
Perf. (%)
€75.00
21.01.24
-
21.01.25
-2.67%
03.02.24

Could be worthwhile Investment >10% per year
buy
Immunic Inc.

Start price
Target price
Perf. (%)
€1.02
20.01.24
€2.50
30.06.24
3.24%
30.06.24

Could be very worthwhile Investment >20% year
buy
Stef Tfe

Start price
Target price
Perf. (%)
€118.60
20.01.24
-
20.01.25
2.70%
03.02.24

Could be worthwhile Investment >10% per year
buy
Mercialys Inh.

Start price
Target price
Perf. (%)
€10.56
20.01.24
-
20.01.25
-0.57%
03.02.24

Could be worthwhile Investment >10% per year
Carparts.com Inc.

Start price
Target price
Perf. (%)
€0.94
19.01.24
-
19.02.24
-
22.01.24

Probably not worthwhile Investment
buy
ProQR Therapeutics N.V.

Start price
Target price
Perf. (%)
€1.95
18.01.24
-
18.01.25
-14.44%
21.01.24

Could be worthwhile Investment >10% per year
buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.98
18.01.24
-
18.01.25
-3.63%
20.01.24

Could be worthwhile Investment >10% per year
buy
Allakos Inc

Start price
Target price
Perf. (%)
€0.99
17.01.24
-
17.01.25
8.55%
21.01.24

Risky Investment
buy
VGP N.V.

Start price
Target price
Perf. (%)
€107.00
17.01.24
-
17.01.25
0.84%
31.01.24

buy
Altira AG

Start price
Target price
Perf. (%)
€9.50
16.01.24
-
16.01.25
-6.84%
18.03.24

buy
Trend Micro Inc.

Start price
Target price
Perf. (%)
€51.30
16.01.24
-
16.01.25
6.63%
15.02.24

buy
Polytec Holding AG

Start price
Target price
Perf. (%)
€3.79
10.01.24
€4.00
10.01.25
0.53%
12.01.24

Dependend from some customers or products
high free float
Below average Marketposition
Little known brand
buy
Kap-beteiligungs-Ag

Start price
Target price
Perf. (%)
€14.20
10.01.24
€17.00
10.01.25
-2.82%
20.01.24

Capable Management
Undervalued
Top 10 in its market
Future proof or reliable business model
buy
SGL Carbon SE

Start price
Target price
Perf. (%)
€6.51
10.01.24
€0.000
10.01.25
-9.38%
20.01.24

Higher EBIT margin than peer group
EBIT growth >5% per year expected
Very Future proof/growth oriented business model
Revenue growth >5% per year expected
buy
H&R GmbH & Co. KGaA

Start price
Target price
Perf. (%)
€4.87
10.01.24
€6.00
10.01.25
-1.23%
20.01.24

Good culture
Revenue growth >5% per year expected
Capable Management
Little innovation